ES2100953T3 - Expresion en lineas linfoblastoides humanas no tumorales con un vector integrante. - Google Patents

Expresion en lineas linfoblastoides humanas no tumorales con un vector integrante.

Info

Publication number
ES2100953T3
ES2100953T3 ES91914319T ES91914319T ES2100953T3 ES 2100953 T3 ES2100953 T3 ES 2100953T3 ES 91914319 T ES91914319 T ES 91914319T ES 91914319 T ES91914319 T ES 91914319T ES 2100953 T3 ES2100953 T3 ES 2100953T3
Authority
ES
Spain
Prior art keywords
expression
integrating vector
lines
human lymphoblastoid
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91914319T
Other languages
English (en)
Inventor
Annick Ballay
Georges Boffa
Jean-Pierre Cartron
Stany Chretien
Patrick Lambin
Claude Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FOND NAT TRANSFUSION SANGUINE
Original Assignee
FOND NAT TRANSFUSION SANGUINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FOND NAT TRANSFUSION SANGUINE filed Critical FOND NAT TRANSFUSION SANGUINE
Application granted granted Critical
Publication of ES2100953T3 publication Critical patent/ES2100953T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE LINEAS CELULARES HUMANAS PARA LA PRODUCCION, A ESCALA INDUSTRIAL, DE PROTEINAS HETEROLOGAS, MAS ESPECIALMENTE DE INTERES TERAPEUTICO, DESPUES DE LA MANIPULACION GENETICA DE SU SECUENCIA DE CODIFICACION E INSERCION EN UN VECTOR APROPIADO. LAS LINEAS CELULARES SON LINEAS LINFOBLASTOIDES NO TUMORALES INMORTALIZADAS POR EBV. LA INVENCION SE REFIERE IGUALMENTE A LA CONSTRUCCION DEL "PLASMIDE" VECTOR, DEL TIPO INTEGRANTE QUE LLEVA UNA CASSETTE DE EXPRESION CONCEBIDA PARA FAVORECER LA EXPRESION OPTIMA DE SECUENCIAS DEL ADN (CUALQUIERA DE LA CLASE DE ACIDOS NUCLEICOS QUE CONTIENEN DEOXIRRIBOSA) HETEROLOGO EN LAS CELULAS LINFOBLASTOIDES.
ES91914319T 1991-08-01 1991-08-01 Expresion en lineas linfoblastoides humanas no tumorales con un vector integrante. Expired - Lifetime ES2100953T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR1991/000636 WO1993003163A1 (fr) 1991-08-01 1991-08-01 Expression dans des lignees lymphoblastoides humaines non-tumorales avec un vecteur integratif

Publications (1)

Publication Number Publication Date
ES2100953T3 true ES2100953T3 (es) 1997-07-01

Family

ID=9408881

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91914319T Expired - Lifetime ES2100953T3 (es) 1991-08-01 1991-08-01 Expresion en lineas linfoblastoides humanas no tumorales con un vector integrante.

Country Status (7)

Country Link
EP (1) EP0596881B1 (es)
JP (1) JPH06508982A (es)
AT (1) ATE150486T1 (es)
DE (1) DE69125292T2 (es)
DK (1) DK0596881T3 (es)
ES (1) ES2100953T3 (es)
WO (1) WO1993003163A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009399A2 (en) * 1994-09-23 1996-03-28 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
ES2378272T3 (es) * 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
ATE384785T1 (de) 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
NZ542585A (en) 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004691A1 (en) * 1986-12-16 1988-06-30 Gist-Brocades N.V. Molecular cloning and expression of human il-3

Also Published As

Publication number Publication date
EP0596881B1 (fr) 1997-03-19
JPH06508982A (ja) 1994-10-13
WO1993003163A1 (fr) 1993-02-18
DK0596881T3 (da) 1997-10-13
DE69125292T2 (de) 1997-09-25
ATE150486T1 (de) 1997-04-15
DE69125292D1 (de) 1997-04-24
EP0596881A1 (fr) 1994-05-18

Similar Documents

Publication Publication Date Title
NO885659L (no) Mycobakterielle rekombinanter og peptider.
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
DK320686D0 (da) Ekspressionskontrolsekvenser
UA27706C2 (uk) Спосіб одержання гетерологічного поліпептиду
GB8610600D0 (en) Transformation of trichoderma
NO303831B1 (no) Isolert DNA-sekvens, vektor, vertscelle, polypeptid og anvendelse in vitro av polypeptidet ved en fremgangsmÕte for transfeksjon av hematopoeseceller med eksogen DNA
ES2013324A6 (es) Un metodo mejorado para producir una proteina heterologa.
DK0666914T3 (da) Hidtil ukendt P-selectin-ligandprotein
MY101203A (en) Production of thrombin iinhibitors.
FI941048A0 (fi) Geloniinipolypeptidin koodaavia DNA-sekvenssejä
EP0260148A3 (en) Improved recombinant expression method, vector and transformed cells
ATE150486T1 (de) Expression in nicht-tumorbildenden menschlichen lymphoblasten zellinien mit einem integrierenden vektor
GB8626878D0 (en) Dna
DK27885A (da) Fremstilling af peptider
AU4030789A (en) Genetic identification employing dna probes of variable number tandem repeat loci
NZ239357A (en) Human mk gene and protein sequence
KR880700855A (ko) 진핵생물 단백질을 발현시키는 개선된 방법
DK509886D0 (da) Udtrykkelsesforoegende dna-sekvenser
AU604122B2 (en) An episomal vector for the expression of selected dna fragments coding for polypeptides in mammalian cells and methods for the production thereof
NO175872C (no) Plasmidvektor, fremgangsmåte for fremstilling av peptider og myelomcelle
FI861559L (fi) Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut
SE8901715L (sv) En plasmid dna-konstruktion innehaallande dna-sekvenser
DK732788A (da) Mycobakterielle rekombinanter og peptider

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 596881

Country of ref document: ES